Immuno-Biological Laboratories Co., Ltd. (JP:4570)
:4570
Want to see JP:4570 full AI Analyst Report?
Total Valuation
Immuno-Biological Laboratories Co., Ltd. has a market cap or net worth of ¥8.49B. The enterprise value is ¥9.24B.
Market Cap¥8.49B
Enterprise Value¥9.24B
Share Statistics
Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,314,590
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Immuno-Biological Laboratories Co., Ltd.’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 13.81%.
Return on Equity (ROE)0.18
Return on Assets (ROA)0.15
Return on Invested Capital (ROIC)13.81%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee17.63M
Profits Per Employee5.77M
Employee Count57
Asset Turnover0.47
Inventory Turnover0.80
Valuation Ratios
The current PE Ratio of Immuno-Biological Laboratories Co., Ltd. is 25.2. Immuno-Biological Laboratories Co., Ltd.’s PEG ratio is 1.18.
PE Ratio25.2
PS Ratio12.44
PB Ratio6.78
Price to Fair Value6.78
Price to FCF46.69
Price to Operating Cash Flow0.00
PEG Ratio1.18
Income Statement
In the last 12 months, Immuno-Biological Laboratories Co., Ltd. had revenue of 1.00B and earned 329.01M in profits. Earnings per share was 35.33.
Revenue1.00B
Gross Profit700.28M
Operating Income281.28M
Pretax Income300.56M
Net Income329.01M
EBITDA299.82M
Earnings Per Share (EPS)35.33
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Immuno-Biological Laboratories Co., Ltd. pays an annual dividend of ¥7.441, resulting in a dividend yield of ―
Dividend Per Share¥7.441
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.91
52-Week Price Change76.48%
50-Day Moving Average1.29K
200-Day Moving Average1.19K
Relative Strength Index (RSI)19.47
Average Volume (3m)23.51K
Important Dates
Immuno-Biological Laboratories Co., Ltd. upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Immuno-Biological Laboratories Co., Ltd. as a current ratio of 5.68, with Debt / Equity ratio of 9.61%
Current Ratio5.68
Quick Ratio4.31
Debt to Market Cap0.01
Net Debt to EBITDA-2.71
Interest Coverage Ratio211.01
Taxes
In the past 12 months, Immuno-Biological Laboratories Co., Ltd. has paid -28.45M in taxes.
Income Tax-28.45M
Effective Tax Rate-0.09
Enterprise Valuation
Immuno-Biological Laboratories Co., Ltd. EV to EBITDA ratio is 38.98, with an EV/FCF ratio of 43.66.
EV to Sales11.63
EV to EBITDA38.98
EV to Free Cash Flow43.66
EV to Operating Cash Flow38.81
Balance Sheet
Immuno-Biological Laboratories Co., Ltd. has ¥903.75M in cash and marketable securities with ¥196.94M in debt, giving a net cash position of ¥706.80M billion.
Cash & Marketable Securities¥903.75M
Total Debt¥196.94M
Net Cash¥706.80M
Net Cash Per Share¥75.88
Tangible Book Value Per Share¥197.93
Margins
Gross margin is 70.35%, with operating margin of 27.99%, and net profit margin of 32.74%.
Gross Margin70.35%
Operating Margin27.99%
Pretax Margin29.91%
Net Profit Margin32.74%
EBITDA Margin29.83%
EBIT Margin27.99%
Analyst Forecast
The average price target for Immuno-Biological Laboratories Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast3.66%
EPS Growth Forecast32.11%